Kornitzer Capital Management Inc. KS Buys 60,531 Shares of Iqvia Holdings Inc (NYSE:IQV)

Kornitzer Capital Management Inc. KS increased its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 68.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,741 shares of the medical research company’s stock after purchasing an additional 60,531 shares during the quarter. Kornitzer Capital Management Inc. KS owned about 0.08% of Iqvia worth $23,932,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Investec Asset Management LTD bought a new stake in shares of Iqvia during the second quarter valued at approximately $340,389,000. BlackRock Inc. lifted its holdings in Iqvia by 12.0% in the first quarter. BlackRock Inc. now owns 12,290,692 shares of the medical research company’s stock valued at $1,768,016,000 after buying an additional 1,313,508 shares during the period. FMR LLC lifted its holdings in Iqvia by 27.5% in the first quarter. FMR LLC now owns 5,376,239 shares of the medical research company’s stock valued at $773,372,000 after buying an additional 1,158,248 shares during the period. Janus Henderson Group PLC lifted its holdings in Iqvia by 19.3% in the second quarter. Janus Henderson Group PLC now owns 3,630,639 shares of the medical research company’s stock valued at $584,166,000 after buying an additional 588,179 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in Iqvia by 18.2% in the first quarter. AQR Capital Management LLC now owns 3,642,793 shares of the medical research company’s stock valued at $519,972,000 after buying an additional 561,276 shares during the period. 92.29% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $158.53, for a total transaction of $1,100,990.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $160.00, for a total transaction of $15,360,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 198,945 shares of company stock worth $30,860,991. 6.00% of the stock is currently owned by company insiders.



IQV traded up $1.16 during mid-day trading on Tuesday, hitting $156.59. The stock had a trading volume of 33,910 shares, compared to its average volume of 1,069,642. The business’s fifty day simple moving average is $157.96. The company has a debt-to-equity ratio of 1.72, a current ratio of 1.14 and a quick ratio of 1.14. The firm has a market cap of $30.52 billion, a price-to-earnings ratio of 30.58, a price-to-earnings-growth ratio of 1.90 and a beta of 0.88. Iqvia Holdings Inc has a 1-year low of $104.90 and a 1-year high of $164.13.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.38 by $0.01. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same period last year, the business posted $1.29 earnings per share. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. As a group, analysts forecast that Iqvia Holdings Inc will post 5.86 earnings per share for the current year.

Several equities analysts recently weighed in on the stock. Leerink Swann assumed coverage on shares of Iqvia in a report on Tuesday, May 28th. They issued an “outperform” rating and a $136.38 price objective on the stock. Zacks Investment Research upgraded shares of Iqvia from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. JPMorgan Chase & Co. increased their price objective on shares of Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. TheStreet lowered shares of Iqvia from a “b” rating to a “c+” rating in a report on Wednesday, May 1st. Finally, Barclays set a $180.00 price objective on shares of Iqvia and gave the company a “buy” rating in a report on Monday, July 15th. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. Iqvia currently has a consensus rating of “Buy” and an average price target of $161.13.

Iqvia Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: Investing in Growth Stocks

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.